Articles By Anuja Singh

Can AI-Driven Chemistry Partnerships Like Merck–ChemLex Accelerate Drug Discovery?

23 January 2026 Executive Summary Merck has signed a Memorandum of Understanding (MoU) with ChemLex, initiating a strategic…

ByByAnuja Singh Jan 24, 2026
FDA Grants Breakthrough Therapy Status to Lilly’s Folate Receptor-Targeted Ovarian Cancer Candidate

23 January 2026 Executive Summary Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has granted…

ByByAnuja Singh Jan 24, 2026
Despite Geopolitical Tensions, U.S.–China Biotech Interdependence Remains Central

23 January 2026 Executive Summary Industry reports continue to underscore the deep interdependence between U.S. and Chinese biotech…

ByByAnuja Singh Jan 24, 2026
Are China’s Innovation and Cost Advantages Redrawing Global Biopharma Competition?

23 January 2026 Executive Summary Competitive dynamics across global biopharma in 2026 are being fundamentally reshaped by China’s…

ByByAnuja Singh Jan 24, 2026
Is China Outpacing the Global Biopharma Cycle? Innovation and Deal Momentum Accelerate

23 January 2026 Executive Summary China’s biopharma sector is continuing to advance at remarkable speed, with recent analyses…

ByByAnuja Singh Jan 24, 2026
Is China Becoming a Power Center for AI-Led Drug Discovery? Insilico Medicine Strikes $66…

23 January 2026 Executive Summary Artificial-intelligence-driven drug developer Insilico Medicine has entered into a $66 million licensing agreement…

ByByAnuja Singh Jan 24, 2026
Image Not Found
Can AI-Driven Chemistry Partnerships Like Merck–ChemLex Accelerate Drug Discovery?

23 January 2026 Executive Summary Merck has signed a Memorandum of Understanding (MoU) with ChemLex, initiating a strategic…

ByByAnuja Singh Jan 24, 2026
FDA Grants Breakthrough Therapy Status to Lilly’s Folate Receptor-Targeted Ovarian Cancer Candidate

23 January 2026 Executive Summary Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has granted…

ByByAnuja Singh Jan 24, 2026
Despite Geopolitical Tensions, U.S.–China Biotech Interdependence Remains Central

23 January 2026 Executive Summary Industry reports continue to underscore the deep interdependence between U.S. and Chinese biotech…

ByByAnuja Singh Jan 24, 2026
Are China’s Innovation and Cost Advantages Redrawing Global Biopharma Competition?

23 January 2026 Executive Summary Competitive dynamics across global biopharma in 2026 are being fundamentally reshaped by China’s…

ByByAnuja Singh Jan 24, 2026
Is China Outpacing the Global Biopharma Cycle? Innovation and Deal Momentum Accelerate

23 January 2026 Executive Summary China’s biopharma sector is continuing to advance at remarkable speed, with recent analyses…

ByByAnuja Singh Jan 24, 2026
Is China Becoming a Power Center for AI-Led Drug Discovery? Insilico Medicine Strikes $66…

23 January 2026 Executive Summary Artificial-intelligence-driven drug developer Insilico Medicine has entered into a $66 million licensing agreement…

ByByAnuja Singh Jan 24, 2026
Scroll to Top